Market Place
Sourcing Support
OSE Immunotherapeutics to Present a Novel, First-in-Class
15 Apr 2026 //
PHARMIWEB
OSE Immunotherapeutics Announces Its 2026 Financial Calendar
16 Mar 2026 //
GLOBENEWSWIRE
OSE Immunotherapeutics Appoints Marc Le Bozec As CEO
10 Mar 2026 //
PHARMIWEB
Boehringer Ingelheim Ends OSE Partnership Due To Mid-Stage Data
03 Mar 2026 //
BIOSPACE
OSE Refocuses on Late-Stage Lusvertikimab, Tedopi
02 Mar 2026 //
GLOBENEWSWIRE
Half-Year Liquidity Contract Report: Invest Securities
20 Jan 2026 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports First Half 2025 Financial Results
15 Oct 2025 //
GLOBENEWSWIRE
Appointment Of Marc Le Bozec As Interim CEO
03 Oct 2025 //
GLOBENEWSWIRE
Board Of Directors Fully Renewed; Dr. Markus Cappel Re-Elected
30 Sep 2025 //
GLOBENEWSWIRE
OSE Immuno, Inserm, Nantes University Form Partnership
26 Sep 2025 //
GLOBENEWSWIRE
Correction Of Voting Rights And Shares Comprising Share Capital
24 Sep 2025 //
GLOBENEWSWIRE
International Proxy Advisory Firms Back Ose Immunotherapeutics`
22 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Updates on Proceedings Before Sept 30
08 Sep 2025 //
GLOBENEWSWIRE
Ose Immunotherapeutics Strengthens Strategy and Governance
04 Sep 2025 //
GLOBENEWSWIRE
OSE Immuno Proposes Governance Changes, Reaffirms Strategy
25 Aug 2025 //
GLOBENEWSWIRE
Half-Year Liquidity Contract Report with Invest Securities
16 Jul 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics updates information on ongoing procedures
02 Jul 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Publishes Letter to Shareholders
30 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics provides an update on ongoing proceedings
25 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reaffirms Transparent General Meeting
20 Jun 2025 //
GLOBENEWSWIRE
General meeting adjourned from June 25, 2025
11 Jun 2025 //
GLOBENEWSWIRE
Update on The Terms of The Shareholders General Meeting
09 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Accelerates Strategy in Inflammation
04 Jun 2025 //
GLOBENEWSWIRE
Ose Immunotherapeutics: Shareholder documents for June 25, 2025
04 Jun 2025 //
GLOBENEWSWIRE
OSE Immuno Updates on Tedopi in Pancreatic and Lung Cancer
02 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Abstracts Selected for ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
OSE Immuno Appoints Dr. Sonya as Chief Development Officer
13 Jan 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Strengthens Leadership And Executive Team
02 Dec 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports Positive Phase 2 Lusvertikimab Results
24 Jul 2024 //
GLOBENEWSWIRE
OSE Reports Symptom Improvements For Ulcerative Colitis Drug
24 Jul 2024 //
FIERCE BIOTECH
Boehringer and OSE to advance cancer immunotherapy to clinics
04 Jul 2024 //
PHARMACEUTICAL TECHNOLOGY
OSE announces CAR T-cell therapy commercial and revenue sharing agreement.
24 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports On 2024 Meeting And Board Evolution
19 Jun 2024 //
GLOBENEWSWIRE
OSE, Nantes: Positive Renal Transplant Immunotherapy Data
05 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Provides Business and Corporate Update
30 May 2024 //
GLOBENEWSWIRE
Boehringer And OSE Expand Collaboration For Cancer And Cardio-Renal Therapies
22 May 2024 //
PRESS RELEASE
OSE, Boehringer Expand Collaboration For Cancer, Cardio-Renal Treatments
22 May 2024 //
GLOBENEWSWIRE
Boehringer pays OSE $42M to grab new asset, expand into cardio
22 May 2024 //
FIERCE BIOTECH
OSE Immunotherapeutics Reports Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Highlights Advancements and Provides 2024 Outlook
19 Jan 2024 //
BUSINESSWIRE
OSE Immunotherapeutics Announces First Clinical Results for BI 770371
23 Oct 2023 //
BUSINESSWIRE
OSE Immuno Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
06 Jul 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance
20 Jun 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Presents Update on BiCKI®IL-7
15 Jun 2023 //
BUSINESSWIRE
OSE Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
06 Jun 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Reports Full Year 2022 Financial Results
27 Apr 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 OSE-279
23 Dec 2022 //
PHARMAFILE
Gilead Sciences to acquire OSE portfolio company for approximately $405m
16 Aug 2022 //
PHARMACEUTICAL MANUFACTURER
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
13 Jul 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports on 2022 Combined General Shareholder`s Meeting
23 Jun 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces Collaboration with Microsoft
16 Jun 2022 //
BIOSPACE
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
09 Jun 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics: 4 Poster Presentations of Neoepitope Combination Tedopi
23 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Begins Dosing in PI Study of VEL-101/FR104
18 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics To Present at two summits In London and Boston
11 May 2022 //
GLOBENEWSWIRE
BI and OSE Immunotherapeutics Begins Dosing in PI Expansion Trial of BI 765063
03 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1
02 May 2022 //
GLOBENEWSWIRE
OSE Immuno to Present Preclinical Data on BiCKI-IL-7 Cancer Immunotherapy
04 Apr 2022 //
GLOBENEWSWIRE
OSE ImmunoTx Provides Positive Long Term Memory Responses with CoVepiT
16 Mar 2022 //
GLOBENEWSWIRE
